# Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

> **NCT04478708** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 110 (actual)

## Conditions studied

- Obesity

## Interventions

- **BIOLOGICAL:** maridebart cafraglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04478708
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-07
- **Primary completion:** 2022-11-18
- **Final completion:** 2022-11-18
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04478708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04478708, "Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04478708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*